Asian participants' experience in phase 3/3b studies of long‐acting cabotegravir and rilpivirine: Efficacy, safety, pharmacokinetic, and virological outcomes through week 96

Objectives Cabotegravir + rilpivirine (CAB + RPV) dosed monthly or every 2 months is the first complete long‐acting (LA) regimen recommended by treatment guidelines for the maintenance of HIV‐1 virological suppression. This post hoc analysis summarizes outcomes for Asian participants through week 96...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	HIV medicine 2024-03, Vol.25 (3), p.381-390
Hauptverfasser:	Oka, Shinichi, Holohan, Vicki, Shirasaka, Takuma, Choi, Jun Yong, Kim, Yeon‐Sook, Chamay, Nadine, Patel, Parul, Polli, Joseph W., Ford, Susan L., Crauwels, Herta, Garside, Louise, D'Amico, Ronald, Latham, Christine, Solingen‐Ristea, Rodica, Baugh, Bryan, Wyk, Jean
Format:	Artikel
Sprache:	eng
Schlagworte:	Algorithms antiretroviral therapy cabotegravir Effectiveness HIV HIV‐1 Human immunodeficiency virus long‐acting Maintenance Pharmacokinetics Ribonucleic acid rilpivirine RNA Safety
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!